PAH associated with CHD is linked to significant reductions in survival and quality of life, especially for patients progressing to Eisenmenger syndrome.
Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
The use of Ikari-curve left guiding catheters during balloon pulmonary angioplasty was found to allow access to branches not accessible with conventional guiding catheters.
Pulmonary vein sign was found to be easy to detect and to have higher sensitivity and specificity in chronic thromboembolic pulmonary hypertension compared with acute pulmonary embolism.
Adult patients with pulmonary arterial hypertension (PAH) who were also obese had worse disease-specific health-related quality of life compared to patients of normal weight.
In patients with pulmonary hypertension undergoing rehabilitation, greater inclusion of outcome measures is needed to facilitate accurate assessment of the wider effect this intervention.
In patients with pulmonary arterial hypertension, education is necessary to provide a better understanding of the role of palliative care in optimizing quality of life.
